Anti-epiligrin cicatricial pemphigoid and relative risk for cancer

It is not known whether patients with anti-epiligrin cicatricial pemphigoid (AECP) have an increased risk of malignancy. We calculated the expected numbers of cancers in a c hort of 35 such patients based on respective incidence rates for all cancers in the National Cancer Instituteʹs Surveillance, Epidemiology, and End Results (NCI SEER) Registry. Ten patients in this cohort had solitary solid cancers; eight patients developed cancer after onset of AECP (seven within 14 months). The relative risk (RR) for cancer in this cohort was 6·8 (95% confidence intervals [CI]: 3·3-12·5). AECP seems to be associated with an increased relative risk for cancer.